Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Base de dados
Tipo de documento
País/Região como assunto
Intervalo de ano de publicação
1.
Mo Med ; 113(4): 288-292, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-30228480

RESUMO

The U.S. health care system relies on primary care physicians to provide the majority of the dermatologic care-dermatologists see an estimated 30-40% of patients with dermatologic issues.1 Issues related to skin and mucous membrane conditions account for an estimated 8% of all visits to Family Physicians.2 Thus the primary care physician must be prepared to assess patients' with conditions benign or malignant, cosmetic or grave, irritants or harbingers of systemic illness, pathological or normal variant. In this article, three commonly seen and difficult to treat conditions will be reviewed.

2.
Am Fam Physician ; 97(10): 671-672, 2018 05 15.
Artigo em Inglês | MEDLINE | ID: mdl-29763280
3.
PLoS One ; 9(5): e96277, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24816199

RESUMO

OBJECTIVE: Safety net health care centers in the US serve vulnerable and underinsured females. The primary aim of this work was to determine if HPV4 dosing compliance differs between females who receive doses at rural vs. urban core safety net health care locations. METHODS: Females exclusively receiving health care in the Truman Medical Center (TMC) safety net system at the urban core and rural locations were identified by their HPV4 vaccine records. Dates and number of HPV4 doses as well as age, gravidity, parity and race/ethnicity were recorded from the electronic medical record (EMR). Appropriate HPV4 dosing intervals were referenced from the literature. RESULTS: 1259 females, 10-26 years of age, received HPV4 vaccination at either the rural (23%) or urban core location (77%). At the rural location, 23% received three doses on time, equal to the 24% at the urban core. Females seen in the urban core were more likely to receive on-time doublet dosing than on-time triplet dosing (82% vs. 67%, p<0.001). Mistimed doses occurred equally often among females receiving only two doses, as well as those receiving three doses. CONCLUSIONS: Compliance with on-time HPV4 triplet dose completion was low at rural and urban core safety net health clinics, but did not differ by location.


Assuntos
Atenção à Saúde/estatística & dados numéricos , Infecções por Papillomavirus/prevenção & controle , Vacinas contra Papillomavirus/administração & dosagem , População Rural/estatística & dados numéricos , População Urbana/estatística & dados numéricos , Vacinação/estatística & dados numéricos , Adolescente , Adulto , Criança , Atenção à Saúde/métodos , Relação Dose-Resposta Imunológica , Feminino , Disparidades em Assistência à Saúde/estatística & dados numéricos , Humanos , Missouri , Vacinas contra Papillomavirus/imunologia , Cooperação do Paciente/estatística & dados numéricos , Estudos Retrospectivos , Vacinação/métodos , Populações Vulneráveis/estatística & dados numéricos , Adulto Jovem
4.
PLoS One ; 8(8): e71295, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23951123

RESUMO

BACKGROUND: HPV4 is approved as a series of three timed doses expected to result in efficacy against specific HPV infections. Completion rates in the US are quite low at the same time the structure of health care delivery is changing. The aim of this study was to determine how the patient-, clinic- and systems-level characteristics facilitate or hinder the timely completion of three HPV4 doses in both adolescent and adult female populations in a high-risk safety net population. METHODS: This is a retrospective study in which patient-, clinic- and systems-level data are abstracted from the electronic medical record (EMR) for all females 10-26 years of age receiving at least one dose of HPV4 between July 1, 2006 and October 1, 2009. RESULTS: Adults were more likely to complete the three dose series if they had at least one health care visit in addition to their HPV4 visit, (aOR = 1.54 (95% CI:1.10, 2.15). Adults were less likely to complete the three dose series if they received their second HPV4 dose at an acute health care, preventive care or postpartum visits compared to an HPV4-only visit (aOR = 0.31 (95% CI: 0.13, 0.72), 0.12 (0.04, 0.35), 0.30 (0.14, 0.62), respectively). Hispanic adults were less likely than whites to complete the series (aOR = 0.24 (95% CI:0.10, 0.59). 39% of adolescents who completed two doses completed the series. CONCLUSIONS: HPV4 is more likely to be effectively administered to adults in a safety net population if multiple health care needs can be met within the health care system.


Assuntos
Infecções por Papillomavirus/prevenção & controle , Vacinas contra Papillomavirus/administração & dosagem , Adolescente , Adulto , Alphapapillomavirus/isolamento & purificação , Criança , Feminino , Humanos , Programas de Imunização , Esquemas de Imunização , Vacinas contra Papillomavirus/uso terapêutico , Cooperação do Paciente , Estudos Retrospectivos , Estados Unidos , Populações Vulneráveis , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA